Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma
Human γδ T cells have displayed their potential in cancer immunity through efficient tumor killing activities. Besides, they are also known for their capacity of antigen presentation. How to improve γδ T cells' immunotherapeutic effect as the cell vaccine is still a great challenge. Herein, we...
Main Authors: | Yitian Wang, Jian Zhu, Wei Yu, Junjie Wang, Kaishun Xia, Chengzhen Liang, Huimin Tao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-04-01
|
Series: | Journal of Bone Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137418303026 |
Similar Items
-
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
by: Yitian Wang, et al.
Published: (2019-04-01) -
Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy
by: Rebecca E. Burnham, et al.
Published: (2020-11-01) -
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells
by: Vinicia A. Polito, et al.
Published: (2019-11-01) -
Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
by: Yuan Song, et al.
Published: (2020-10-01) -
Imbalance of γδT17/γδTreg cells in the pathogenesis of allergic asthma induced by ovalbumin
by: Xia Yang, et al.
Published: (2018-07-01)